Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

Core Insights - Apellis Pharmaceuticals will present at the Stifel 2025 Healthcare Conference on November 12, 2025, at 2:40 p.m. ET [1] - The company has developed two C3-targeting medicines approved for treating four serious diseases, marking significant advancements in complement science [2] Company Overview - Apellis Pharmaceuticals is a global biopharmaceutical company focused on complement science to create therapies for challenging diseases [2] - The company introduced the first new class of complement medicine in 15 years, including the first therapy for geographic atrophy and the first treatment for patients with C3G or primary IC-MPGN [2] - Apellis believes there is significant potential in targeting C3 for various serious diseases [2]